NCT01080365

Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions

A Single Dose Bioequivalence Study Comparing The Commercial Tablet Formulation To The Clinical Tablet Of Bosutinib In Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Study comparing 2 formulations of bosutinib in healthy subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	SKI-606 (Bosutinib)	500 mg commercial formulation film coated tablet, administered once daily
DRUG	SKI-606 (Bosutinib)	500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily

Timeline

• Start date: 2010-02-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2010-03-04
• Last updated: 2010-09-06

Locations

1 site across 1 country: United States